| Jul 25 |
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
|
| Jul 19 |
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
|
| Jul 18 |
Inventiva announces a €20.1 million issuance of royalty certificates
|
| Jul 8 |
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
|
| Jul 8 |
Inventiva reports updates from MASH/NASH treatment study
|
| Jul 5 |
Inventiva stock gains on financing, MASH study update
|
| Jul 5 |
Inventiva Looking to Raise Additional Funds to Extend Cash Runway
|
| Jul 5 |
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
|
| Jun 21 |
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
|
| Jun 21 |
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
|
